Shen Chong, Zhuo Jian, Wang Jianying
Yangzhou Third People's Hospital, Yangzhou, China.
School of Medicine, Ningbo University, Ningbo, Zhejiang, China.
Sci Rep. 2025 Jul 18;15(1):26111. doi: 10.1038/s41598-025-11495-9.
Clear cell renal cell carcinoma (ccRCC) is a subtype of renal cancer primarily originating from renal tubular epithelial cells. The absence of effective treatments has contributed to its poor prognosis. PDLIM7 is a protein containing PDZ and LIM structural domains, which performs varied functions through interactions with different proteins. To elucidate the role of PDLIM7 in ccRCC, we aimed to investigate its potential functions in relation to drug sensitivity. We analyzed multiple databases to assess the relationship between PDLIM7 expression and clinicopathological features, and conducted survival prognosis analysis. The expression level of PDLIM7 was validated through Western blotting and immunohistochemistry (IHC). We determined the effects and mechanisms of PDLIM7 on cancer cell proliferation, migration, and invasion through cloning assays, scratch assays, and Transwell assays. The functions and potential mechanisms of action of PDLIM7 were analyzed using gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses. Its relationship with drug sensitivity was predicted utilizing the CellMiner database. Our study demonstrated that elevated PDLIM7 expression in ccRCC tissues and cell lines is significantly associated with the prognosis of patients with ccRCC. The knockdown of PDLIM7 markedly reduced the activity of ccRCC cells. KEGG and GO functional enrichment analyses indicated that PDLIM7 is implicated in various biological functions and signaling pathways. Higher levels of PDLIM7 are associated with increased sensitivity to a range of therapeutic agents. In conclusion, PDLIM7 is highly expressed in ccRCC and functions as an oncogene; its knockdown significantly inhibits the activity of ccRCC cells. PDLIM7 may serve as a prognostic marker for ccRCC and represents a potential therapeutic target.
透明细胞肾细胞癌(ccRCC)是一种主要起源于肾小管上皮细胞的肾癌亚型。缺乏有效的治疗方法导致其预后较差。PDLIM7是一种含有PDZ和LIM结构域的蛋白质,它通过与不同蛋白质相互作用发挥多种功能。为了阐明PDLIM7在ccRCC中的作用,我们旨在研究其与药物敏感性相关的潜在功能。我们分析了多个数据库以评估PDLIM7表达与临床病理特征之间的关系,并进行了生存预后分析。通过蛋白质免疫印迹法和免疫组织化学(IHC)验证了PDLIM7的表达水平。我们通过克隆实验、划痕实验和Transwell实验确定了PDLIM7对癌细胞增殖、迁移和侵袭的影响及机制。使用基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析来分析PDLIM7的功能和潜在作用机制。利用CellMiner数据库预测其与药物敏感性的关系。我们的研究表明,ccRCC组织和细胞系中PDLIM7表达升高与ccRCC患者的预后显著相关。敲低PDLIM7可显著降低ccRCC细胞的活性。KEGG和GO功能富集分析表明,PDLIM7参与多种生物学功能和信号通路。较高水平的PDLIM7与对一系列治疗药物的敏感性增加相关。总之,PDLIM7在ccRCC中高表达并作为一种癌基因发挥作用;敲低它可显著抑制ccRCC细胞的活性。PDLIM7可能作为ccRCC的预后标志物,并代表一个潜在的治疗靶点。